Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib

@inproceedings{Koyama2013PharmacodynamicCI,
  title={Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib},
  author={Noriyuki Koyama and Kenichi Saito and Yuki Nishioka and Wataru Yusa and Noboru Yamamoto and Yasuhide Yamada and Hiroshi Nokihara and Fumiaki Koizumi and Kazuto Nishio and Tomohide Tamura},
  booktitle={BMC Cancer},
  year={2013}
}
Lenvatinib (E7080), an oral multi-kinase inhibitor, has inhibitory action on tumor cell proliferation and tumor angiogenesis in preclinical models. We evaluated correlations between pharmacodynamic (PD) biomarkers with patient clinical outcomes in a lenvatinib phase 1 dose-escalation study. Plasma angiogenic proteins were evaluated as potential PD biomarkers of response to lenvatinib in a dose-escalation phase 1 study. Lenvatinib was administered to 27 patients by twice-daily dosing in 3-week… CONTINUE READING